MedPath

Comparing Approaches to Assess Nitric Oxide-dependent Cutaneous Vasodilation

Early Phase 1
Not yet recruiting
Conditions
Endothelial Function
Interventions
Registration Number
NCT06499844
Lead Sponsor
University of Iowa
Brief Summary

The increase in skin blood flow in response to rapid local heating of the skin (i.e., cutaneous vasodilation) is commonly used to assess nitric oxide (NO)-dependent dilation and overall microvascular function. Historically, rapid local heating to 42°C was considered the standard approach for these assessments. More recently, many investigators have adopted rapid local to 39°C instead, based on its larger dependency on NO and therefore improved ability to quantify NO-dependent dilation without the use of pharmacological techniques. However, to date, only one direct methodological comparison between these protocols has been performed.

In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) they examine the blood vessels in a nickel-sized area of the skin in young adults ages 18 - 30 years old. Local heating of the skin at the microdialysis sites is used to explore differences in mechanisms governing microvascular control. As a compliment to these measurements, the investigators also have participants fill out a variety of surveys to assess things such as sleep quality, physical activity, daily stressors, etc.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
56
Inclusion Criteria
  • men and women
  • 18-30 years of age
Exclusion Criteria
  • Current or recent (within 8 wks) use of medication that could conceivably alter microvascular function [including (but not limited to) stimulants, antihypertensives, HMG-CoA reductase inhibitors]
  • Changes or alterations in medication status (starting a new, additional, or different medication or changing the dose of a current medication)
  • Unstable or diagnosed chronic clinical disease, including cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological disease (e.g., hypertension, heart disease, diabetes, hyperlipidemia, psoriasis)
  • Body mass index <18.5 or >35 kg/m2
  • Pregnancy (including a positive urine pregnancy test) or breast-feeding
  • Known allergies to pharmacological agents or study drugs
  • Non-English-speaking. Participants need to understand English to follow instructions and comply with procedures conducted during the screening and experimental visits.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
assessment of microvascular endothelial functionAcetylcholineThe investigators use intradermal microdialysis to deliver acetylcholine, L-NAME, and acetylcholine + L-NAME to the cutaneous microvasculature.
Primary Outcome Measures
NameTimeMethod
Microvascular blood flow response to local heat (39 degrees Celsius)baseline study visit (average of 4 hours)

cutaneous vascular vasodilator response to 39 degree local heat; measured with laser-Doppler flowmetry coupled with intradermal microdialysis delivery of lactated Ringer's, followed by L-NAME.

Microvascular blood flow response to local heat (42 degrees Celsius)baseline study visit (average of 4 hours)

cutaneous vascular vasodilator response to 42 degree local heat; measured with laser-Doppler flowmetry coupled with intradermal microdialysis delivery of lactated Ringer's, followed by L-NAME.

Microvascular blood flow response to acetylcholinebaseline study visit (average of 4 hours)

cutaneous vascular vasodilator response to exogenous acetylcholine perfusion; measured with laser-Doppler flowmetry coupled with intradermal microdialysis delivery of acetylcholine alone or co-infused with L-NAME

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Iowa

🇺🇸

Iowa City, Iowa, United States

© Copyright 2025. All Rights Reserved by MedPath